Valuation Abbott Laboratories Börse Stuttgart
Stocks
ABL
US0028241000
Medical Equipment, Supplies & Distribution
|
Market Closed -
Börse Stuttgart
01:27:06 03/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 86.46 EUR | +0.61% |
|
-3.20% | -18.51% |
| 02/10 | Weak Jobs Lead to Stronger Stocks |  |
| 02/10 | Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms | RE |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,41,365 | 1,91,427 | 1,91,088 | 1,96,184 | 2,17,859 | 1,68,712 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -22.56% | - | - |
| Enterprise Value (EV) 1 | 2,49,166 | 1,98,318 | 1,98,871 | 2,02,693 | 2,22,266 | 1,92,651 | 1,89,669 | 1,85,979 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -13.32% | -1.55% | -1.95% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 27.6x | 21.4x | 19.1x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.52x | 3.38x | 3.2x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -5.38x | 0.7x | 1.6x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.36x | 3.09x | 2.9x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.84x | 3.48x | 3.19x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 14.8x | 13.1x | 11.7x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 16.4x | 14.6x | 13x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 25.5x | 21.3x | 19.4x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.92% | 4.7% | 5.16% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.57 | 2.741 | 2.899 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.64% | 2.81% | 2.97% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.529 | 4.553 | 5.109 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 72.8% | 60.2% | 56.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,205 | 54,531 | 58,255 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,988 | 14,491 | 15,861 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,720 | 13,022 | 14,320 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,302 | 7,978 | 8,912 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 97.50 | 97.50 | 97.50 |
| Nbr of stocks (in thousands) | 17,14,968 | 17,43,574 | 17,36,059 | 17,34,455 | 17,38,834 | 17,30,383 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.63x | 3.84x | 14.83x | 2.64% | 17TCr | |
| 18.25x | 3.37x | 12.04x | 3.26% | 11TCr | |
| 21.42x | 4.21x | 14.72x | 1.31% | 11TCr | |
| 25.26x | 2.48x | 10.04x | 2.86% | 7.39TCr | |
| 16.92x | 0.2x | 12.42x | 0.77% | 5.9TCr | |
| 29.48x | 7.29x | 18.84x | 1.36% | 5.13TCr | |
| 34.07x | 3.32x | 11.38x | 2.22% | 4.82TCr | |
| 35.11x | 8.73x | 24.55x | -.--% | 4.08TCr | |
| 34.3x | 6.01x | 18.87x | -.--% | 3.22TCr | |
| Average | 26.94x | 4.38x | 15.30x | 1.6% | 7.67TCr | |
| Weighted average by Cap. | 25.35x | 3.98x | 14.47x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABL Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
